Recent advances in treatment of youth with Type 1 diabetes: better care through technology

被引:50
作者
Tamborlane, WV
Bonfig, W
Boland, E
机构
[1] Yale Univ, Sch Med, Dept Paediat, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Childrens Clin Res Ctr, New Haven, CT USA
关键词
Type 1 diabetes mellitus; insulin analogues; inhaled insulin; glucose sensing;
D O I
10.1046/j.1464-5491.2001.00626.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
While treatment of Type 1 diabetes mellitus (T1DM) in children and adolescents is especially difficult, recent technological advances have provided new therapeutic options to clinicians and patients. The urgency to achieve strict diabetes control and the introduction of new and improved insulin pumps have been accompanied by a marked increase in use of continuous subcutaneous insulin infusion (CSII) therapy in youth with diabetes. Results of clinical outcome studies indicate that CSII provides a safe and effective alternative to multiple daily injection (MDI) therapy, even when employed in a regular clinic setting in a large number of children. The safety and efficacy of CSII is further enhanced by the introduction of lispro and aspart insulin. The sharper peaks and shorter duration of action of these very rapid-acting insulin analogues provides a means to achieve better control of post-prandial hyperglycaemia with less late post-prandial and nocturnal hypoglycaemia. Glargine insulin, a soluble and essentially peakless long-acting insulin analogue, may provide a better basal insulin for MDI regimens, but there are limited published data with this agent in children with T1DM. A number of systems for pulmonary delivery of insulin are in development and preliminary results of Phase III studies have been promising. Like CSII, inhaled insulin allows the child to take bolus insulin doses before each meal without having to take a premeal injection. A major obstacle to effective treatment is that self-monitoring of three to four blood glucose levels a day often misses the marked glycaemic excursions that characterize T1DM in young patients. On the other hand, new continuous glucose sensing systems provide a wealth of data that can be used to optimize basal and bolus therapy, regardless of how insulin is administered. Even more important, we may finally be at the threshold of development of a practically applicable artificial pancreas.
引用
收藏
页码:864 / 870
页数:7
相关论文
共 43 条
[1]   CLINICAL CONTROL OF DIABETES BY ARTIFICIAL PANCREAS [J].
ALBISSER, AM ;
LEIBEL, BS ;
EWART, TG ;
DAVIDOVAC, Z ;
BOTZ, CK ;
ZINGG, W ;
SCHIPPER, H ;
GANDER, R .
DIABETES, 1974, 23 (05) :397-404
[2]   INSULIN RESISTANCE OF PUBERTY - A DEFECT RESTRICTED TO PERIPHERAL GLUCOSE-METABOLISM [J].
AMIEL, SA ;
CAPRIO, S ;
SHERWIN, RS ;
PLEWE, G ;
HAYMOND, MW ;
TAMBORLANE, WV .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (02) :277-282
[3]   IMPAIRED INSULIN ACTION IN PUBERTY - A CONTRIBUTING FACTOR TO POOR GLYCEMIC CONTROL IN ADOLESCENTS WITH DIABETES [J].
AMIEL, SA ;
SHERWIN, RS ;
SIMONSON, DC ;
LAURITANO, AA ;
TAMBORLANE, WV .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (04) :215-219
[4]  
[Anonymous], 1995, DIABETES, V44, P968
[5]   Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM [J].
Attia, N ;
Jones, TW ;
Holcombe, J ;
Tamborlane, WV .
DIABETES CARE, 1998, 21 (05) :817-821
[6]   Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study [J].
Bode, BW ;
Gross, TM ;
Thornton, KR ;
Mastrototaro, JJ .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1999, 46 (03) :183-190
[7]  
Boland EA, 2000, DIABETES, V49, pA98
[8]   Continuous subcutaneous insulin infusion - A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes [J].
Boland, EA ;
Grey, M ;
Oesterle, A ;
Fredrickson, L ;
Tamborlane, WV .
DIABETES CARE, 1999, 22 (11) :1779-1784
[9]   Insulin glargine [J].
Bolli, GB ;
Owens, DR .
LANCET, 2000, 356 (9228) :443-445
[10]   Inhaled human insulin treatment in patients with type 2 diabetes mellitus [J].
Cefalu, WT ;
Skyler, JS ;
Kourides, IA ;
Landschulz, WH ;
Balagtas, CC ;
Cheng, SL ;
Gelfand, RA .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (03) :203-207